# HL-085 in NRAS-mutated Advanced Melanoma

> **NCT05217303** · PHASE2 · COMPLETED · sponsor: **Shanghai Kechow Pharma, Inc.** · enrollment: 100 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** HL-085

## Key facts

- **NCT ID:** NCT05217303
- **Lead sponsor:** Shanghai Kechow Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-02
- **Primary completion:** 2023-02-19
- **Final completion:** 2023-02-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217303, "HL-085 in NRAS-mutated Advanced Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05217303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*